Infliximab biosimilar is under clinical development by Celltrion and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

South Korea’s Celltrion Healthcare has begun a UK trial of its infliximab biosimilar to see if the drug can accelerate recovery from symptoms of COVID-19. The company noted that COVID-19 is ...

Objectives: A large-scale postmarketing surveillance (PMS) study was carried out to determine the safety profile of infliximab in Japanese patients with rheumatoid arthritis (RA). Methods: The PMS ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) was the target of a significant decrease in short interest in the month of ...

Fatigue in IBD 1 year after diagnosis does not appear to be less prevalent even when applying stricter definitions of disease ...

A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn's disease, a new ...

A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn’s disease.A new ...

Christie at the ‘Telling It Like It Is’ exhibition of female crime writers in July 2023 Pic: Donna-Lisa Healy Photography A ...

is horse racing legal in idaho Jiahe Biopharma's "Infliximab" biosimilar drug has been approved for listing Fosun Pharma: ...

Early treatment of pediatric Crohn’s disease with anti-tumor necrosis factor medications can substantially reduce the risk of ...